miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors-Reference-Cited by-同舟云学术

miR-182-Mediated Downregulation of BRCA1 Impacts DNA Repair and Sensitivity to PARP Inhibitors

Published:2011-01 Issue:2 Volume:41 Page:210-220
ISSN:1097-2765
Container-title:Molecular Cell
language:en
Short-container-title:Molecular Cell

Author:

Moskwa Patryk,Buffa Francesca M.,Pan Yunfeng,Panchakshari Rohit,Gottipati Ponnari,Muschel Ruth J.,Beech John,Kulshrestha Ritu,Abdelmohsen Kotb,Weinstock David M.,Gorospe Myriam,Harris Adrian L.,Helleday Thomas,Chowdhury Dipanjan

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology

Reference68 articles.

1. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer;Atchley;J. Clin. Oncol.,2008

2. Negative regulation of BRCA1 gene expression by HMGA1 proteins accounts for the reduced BRCA1 protein levels in sporadic breast carcinoma;Baldassarre;Mol. Cell. Biol.,2003

3. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues;Bandres;Mol. Cancer,2006

4. MicroRNAs: target recognition and regulatory functions;Bartel;Cell,2009

5. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin;Bhattacharyya;J. Biol. Chem.,2000

Cited by 373 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Overexpressed MicroRNAs miRs-182, 155, 493, 454, and U6 snRNA and Underexpressed let-7c, miR-328, and miR-451a as Potential Biomarkers in Invasive Breast Cancer and Their Clinicopathological Significance;Oncology;2024-08-12

2. Drug resistance in ovarian cancer: from mechanism to clinical trial;Molecular Cancer;2024-03-28

3. DNA damage response, a double-edged sword for vascular aging;Ageing Research Reviews;2023-12

4. Mutual regulation of TGFβ-induced oncogenic EMT, cell cycle progression and the DDR;Seminars in Cancer Biology;2023-12

5. Molecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions;Clinical Breast Cancer;2023-12